<DOC>
	<DOCNO>NCT00498472</DOCNO>
	<brief_summary>Hospitalizations acute heart failure syndrome ( AHFS ) associate high rehospitalisation mortality rate . The aim study assess measurement NT-proBNP level discharge may improve prognosis patient recently admit hospital AHFS</brief_summary>
	<brief_title>NT-proBNP Optimization Treatment After Recent Acute Heart Failure Trial</brief_title>
	<detailed_description>Study population . We include study patient admit institute AHFS New York Heart Association ( NYHA ) class III IV symptom . All patient evidence symptomatic heart failure symptom rest minimal exercise require intravenous therapy . All patient give write informed consent entry study . Patients clinical laboratory evidence acute coronary syndrome well patient major arrhythmia exclude condition likely main cause symptom . In contrast , patient aspecific electrocardiographic ST segment change and/or slight elevation plasma troponin level may include condition know frequently associate AHFS generally possible establish extent cause rather consequence hemodynamic decompensation . The patient coronary revascularization procedure ( either PTCA CABG ) plan next 3 month patient non cardiac concomitant disease may influence outcome primary factor exclude study . Study design . Blood sample assessment NT-proBNP plasma level obtain patient least two time interval : pre-discharge ( e.g . 24 72 hour plan date discharge ) discharge ( e.g . day discharge ) . Pre-discharge sample take patient clinically stable , oral drug dos plan administer discharge . All patient randomise accord previous randomization scheme two group : control group , result NT-proBNP level know retrospectively , end trial ; intervention group , value pre-discharge NT-proBNP plasma level know investigator day blood sample . In intervention group , possible change medical treatment , need , prolong hospitalization , case pre-discharge NT-proBNP level &gt; 3000 pg/mL . This value associate 13-fold increase mortality heart failure rehospitalisation rate patient recently admit AHFS . ( Eur J Heart Fail . 2007 Jun 15 ; [ Epub ahead print ] PMID : 17573240 ) The following change treatment possible : increase dose diuretic , association different diuretic ( e.g . aldosterone antagonist ) ; combination digoxin therapy ; increase dose rennin-angiotensin inhibitor ; association angiotensin receptor blocker ; association nitrate ; short course i.v . diuretic , vasodilator and/or inotropic therapy . Plasma level NT-proBNP measure discharge . It aim use intervention group treatment modality similar may expect NT-proBNP level use guide therapy . Therefore , clinical investigator assess patient may require laboratory knowledge discharge NT-proBNP level delay patient 's discharge adjust treatment , case response treatment ( e.g . decrease NT-proBNP level ) find insufficient . In intervention group , assessment plasma NT-proBNP level repeat 7 21 day discharge . If NT-propBNP level still elevate time , investigator may change medical treatment . A satisfactory change NT-ProBNP plasma level define priori either one following : ) decrease plasma NT-proBNP 3000 pg/mL ( value associate favourable prognosis previous study group ) ; b ) decrease &gt; 30 % first value detect ( i.e . measure 24 72 hour discharge ) . This percentage base previous study regard prognostic value serial change NT-proBNP level spontaneous week week variability clinically stable heart failure patient . Additional exam . During hospitalization , patient least daily assessment clinical condition medical treatment titrate obtain clinical stability symptom relief , possible . The investigator unaware randomization code day pre-discharge sample . No difference baseline clinical characteristic , hospitalization duration plan discharge in-hospital treatment expect two study group . All patient undergo standard Doppler-echocardiography chest-X ray least hospitalization . The 6 minute walk distance measure patient clinically stable , discharge . Follow-up . Each patient undergo clinical visit telephone assessment his/her clinical condition 1 3 month discharge every 6 month thereafter end study . Unplanned ambulatory visit allow base clinical condition need patient . An echocardiographic exam assessment 6 minute walk distance repeat 6 month initial hospitalization . Standard laboratory exam repeat 1 , 3 6 month discharge Outcome measure Main outcome : Incidence unplanned cardiovascular hospitalization cardiac death 6 month control intervention group . Secondary outcome : Incidence cardiac mortality alone ; combine incidence cardiac death , cardiovascular hospitalization unplanned ambulatory visit ; number day spend hospital first hospitalization ; number day spend hospital follow-up ; change leave ventricular ejection fraction , volume fill pattern first hospitalization 6 month ; change NYHA class 6 minute walk distance ; change renal function baseline discharge discharge reassessment 1 , 3 6 month .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients admit acute HF New York Heart Association class III IV symptom . Requirement intravenous therapy All patient give write informed consent Clinical laboratory evidence acute coronary syndrome Major arrhythmia main cause symptom Patients coronary revascularization procedure ( either PTCA CABG ) plan next 3 month Non cardiac concomitant disease may important influence outcome primary factor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>BNP</keyword>
	<keyword>heart failure</keyword>
</DOC>